Randomized trial · people

Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3

Checked against the paper Randomized trialPublished by PepVault

The takeaway

For people on oral semaglutide, this head-to-head trial found it lowered HbA1c less than orforglipron over a year, but with fewer gut side effects and fewer people stopping treatment.

Kind
Randomized trial
Studied in
People
Number studied
1698
Published
2026
Journal
Lancet

What they tested

Does daily oral orforglipron lower blood sugar at least as well as daily oral semaglutide in adults with type 2 diabetes whose sugar stayed too high on metformin?

How the study was done

A randomized, open-label (everyone knew which drug they got) phase 3 trial of 1698 adults with type 2 diabetes on metformin, at 131 sites in Argentina, China, Japan, Mexico and the USA. People were assigned to one of four daily pills for 52 weeks: orforglipron 12 mg or 36 mg, or oral semaglutide 7 mg or 14 mg.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking semaglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

From a starting HbA1c (a 3-month average of blood sugar) of 8.3%, the average change at 52 weeks was -1.23% in the semaglutide 7 mg arm and -1.47% in the 14 mg arm, against -1.71% with orforglipron 12 mg and -1.91% with orforglipron 36 mg. Both orforglipron doses beat both semaglutide doses; for example, orforglipron 36 mg versus semaglutide 14 mg differed by -0.44% (95% CI -0.62 to -0.26). Stomach and gut side effects, mostly mild to moderate, hit 37% and 45% of the semaglutide arms versus 59% and 58% of the orforglipron arms. Fewer people quit semaglutide because of side effects (4% and 5%, versus 9% and 10%), and pulse rose less on semaglutide (1.0 and 1.5 bpm, versus 3.7 and 4.7 bpm).

What it doesn’t show

Participants and staff knew which drug was given, the trial ran 52 weeks, and it only included people already taking metformin. The trial was funded by Eli Lilly.

The paper

Rosenstock et al. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. Lancet. 2026.

The compounds

More studies on Semaglutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking semaglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo